In this article, we will look at the 8 Cheap Large Cap Stocks to Buy Now.
Cheap large-cap stocks are getting more attention as investors are looking past the market’s most crowded winners and are now putting more weight on the current entry points. This matters in a market where broad indices still look expensive even as plenty of individual large-cap names have already reset. Large caps do not usually get framed as bargain territory, but that changes when sentiment cools, leadership broadens, and investors begin separating the index from the stocks inside it.
J.P. Morgan Asset Management says the “value factor remains attractive globally” and that the “quality factor is also inexpensive in the U.S.” Fidelity makes a similar point from the stock-picking side, saying investors can use volatility to “buy quality stocks” at “discounted prices.” At the same time, market pullbacks can create chances to pick up names at “temporarily marked-down prices.” Putnam Investments adds that while the S&P 500 is “more expensive than average,” “many in this cohort are trading in line with or cheaper than their historical averages.” The headline market may not look cheap, but parts of the large-cap universe still do.
Against this backdrop, large-cap stocks with lower valuations become harder to ignore. That brings us to the 8 Cheap Large Cap Stocks to Buy Now.
Our Methodology
We used the Finviz screener to identify large-cap stocks that are trading below a forward P/E of 15 and limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
8. Toyota Motor Corporation (NYSE:TM)
On April 2, 2026, Erste Group downgraded Toyota Motor Corporation (NYSE:TM) to Hold from Buy. Erste Group said Toyota continues to deliver higher profitability than peers, with return on equity and operating margins above sector averages, supported by strong global positioning and demand for hybrid vehicles. However, the firm noted that higher energy prices and weaker consumer confidence in key markets could limit revenue growth despite planned expansion in hybrid production and sales.
On April 1, 2026, Toyota Motor Corporation reported March U.S. sales of 211,617 units, down 8.5%.
Last month, Toyota marked 40 years at its Kentucky plant and announced a $1 billion investment across its Kentucky and Indiana operations as part of a broader plan to invest up to $10 billion in U.S. plants over five years. The investment includes $800 million in Kentucky to support electrification and increase capacity for Camry and RAV4 production, and $200 million in Indiana to expand Grand Highlander capacity alongside Sienna and Lexus TX production.
Toyota Motor Corporation manufactures and sells vehicles and automotive products globally.
7. Pfizer Inc. (NYSE:PFE)
On April 9, 2026, BofA lowered the price target on Pfizer Inc. (NYSE:PFE) to $26 from $27 and maintained a Neutral rating. BofA said the change reflects updates made as part of its Q1 preview across large-cap pharma and small-to-mid cap biopharma coverage.
On April 1, 2026, a Belgian court ordered Poland and Romania to accept and pay for EUR 1.9B worth of Covid-19 vaccines from Pfizer, rejecting arguments for non-compliance with a European Commission supply contract. Poland is required to take EUR 1.3B worth of doses and Romania EUR 600M after both had refused delivery citing pandemic developments and other concerns.
On March 24, 2026, Guggenheim raised its price target on Pfizer to $36 from $35 and maintained a Buy rating, citing upcoming Phase 3 data for mevrometostat expected in the second half of 2026 and noting potential upside versus downside scenarios tied to the trial outcome.
On March 23, 2026, Pfizer and Valneva reported Phase 3 VALOR trial results for their Lyme disease vaccine candidate, showing efficacy of 73.2% and 74.8% in two analyses, while noting the first pre-specified statistical criterion was not met due to fewer cases, but indicating plans for regulatory submissions.
Pfizer Inc. develops and commercializes biopharmaceutical products globally.
6. Devon Energy Corporation (NYSE:DVN)
On April 7, 2026, BMO Capital raised the price target on Devon Energy Corporation (NYSE:DVN) to $60 from $55 and maintained an Outperform rating as part of a broader update incorporating Q1 mark-to-market assumptions tied to the Iran war and ongoing natural gas oversupply in North America. BMO Capital said oil markets remain highly sensitive to geopolitical developments, with potential outcomes ranging from a $75–$85 per barrel range if flows normalize to $150–$200 in an escalation scenario, while maintaining its view that the conflict is likely to wind down by the end of April.
On March 27, 2026, Morgan Stanley raised its price target on Devon Energy to $59 from $46 and maintained an Overweight rating. Morgan Stanley said oil, LNG, and refining margins are at their highest levels since 2022 and may not revert quickly, raising its 2026 price assumptions for WTI, NGLs, and refining margins, with EBITDA estimates for North American energy names increasing significantly.
On March 23, 2026, Truist initiated coverage on Devon Energy with a Buy rating and a $63 price target. Truist said activist pressure and developments related to the Coterra transaction could lead to additional changes ahead of the expected Q2 close, while noting its model assumes the deal proceeds as planned and valuation could improve with successful integration.
Devon Energy Corporation explores and produces oil, natural gas, and natural gas liquids in the United States.
5. Synchrony Financial (NYSE:SYF)
On April 9, 2026, Wells Fargo lowered the price target on Synchrony Financial (NYSE:SYF) to $95 from $100 and maintained an Overweight rating. Wells Fargo said investor focus is shifting from geopolitical risk to concerns around AI-driven job impacts, noting sentiment appears bearish, while adding that credit performance and card spending remain solid and stimulus effects are expected to offset higher gas prices, with banks likely to maintain a constructive view on consumers.
On April 6, 2026, Seaport Research lowered its price target on Synchrony Financial to $84 from $95 previously and maintained a Buy rating on the shares. Seaport Research said it reduced estimates due to lower-than-expected net interest margin expansion in 2026.
Similarly, Barclays analyst Terry Ma lowered the price target on Synchrony Financial to $82 from $93 previously and maintained an Overweight rating on the shares. Terry Ma said valuations across the consumer finance group have declined below historical averages amid macro uncertainty, while noting favorable risk/reward among preferred names.
Synchrony Financial provides consumer credit products and financial services in the United States.
4. MetLife, Inc. (NYSE:MET)
On April 9, 2026, UBS raised the price target on MetLife, Inc. (NYSE:MET) to $102 from $98 and maintained a Buy rating. UBS said the update reflects changes across the North American life insurance group ahead of Q1 earnings, noting continued focus on disability margins with “relatively limited wiggle-room” given cyclicality and economic uncertainty, while rolling its valuation to 2027 estimates.
On the same day, MetLife Investment Management said it originated approximately $26B in private fixed income transactions in 2025, bringing total assets under management on its platform to $144.7B as of December 31, 2025. The platform includes private corporate and infrastructure debt, asset-based finance, residential loans, and sustainable finance, with originations including $8.9B in residential credit, $6.8B in corporate debt, $5.7B in infrastructure debt, and $4.5B in asset-based finance.
On April 8, 2026, Barclays lowered its price target on MetLife to $89 from $92 and maintained an Overweight rating. Barclays said premium growth and broker organic growth are expected to remain sluggish, but noted that margins and capital deployment should continue to support book value growth.
MetLife, Inc. provides insurance, asset management, and financial services globally.
3. The Hartford Insurance Group, Inc. (NYSE:HIG)
On April 9, 2026, Cantor Fitzgerald analyst Ryan Tunis lowered the price target on The Hartford Insurance Group, Inc. (NYSE:HIG) to $160 from $165 and maintained an Overweight rating. Ryan Tunis said the update reflects changes across the insurance group ahead of Q1 earnings, noting soft market conditions are more reflected in reinsurer valuations than in specialty and commercial lines.
On the same day, The Hartford Insurance Group, Inc. (HIG) appointed Natalie Burns as head of Enterprise Sales & Distribution, effective May 1, reporting to Tracey Ant. Natalie Burns will oversee relationships with key distribution partners and coordinate across Personal and Business Insurance and Employee Benefits sales teams, replacing Stephen Screen, who has moved to a role in Global Specialty.
On April 8, 2026, Barclays lowered its price target on The Hartford Insurance Group, Inc. (HIG) to $159 from $162 and maintained an Overweight rating. Barclays said premium growth and broker organic growth are expected to remain sluggish, but noted margins and capital deployment should continue to support book value growth.
The Hartford Insurance Group, Inc. provides insurance and financial services to individuals and businesses.
2. Teva Pharmaceutical Industries Limited (NYSE:TEVA)
On April 9, 2026, BofA raised the price target on Teva Pharmaceutical Industries Limited (NYSE:TEVA) to $42 from $38 and maintained a Buy rating. BofA said the update reflects changes made as part of its Q1 preview across large-cap pharma and small-to-mid cap biopharma coverage.
On March 30, 2026, Teva Pharmaceutical Industries Limited announced that its applications for a proposed biosimilar to Xolair, oromalizumab, have been accepted for review by both the U.S. FDA and the European Medicines Agency. The filings include a Biologics License Application and a Marketing Authorization Application and cover all approved indications of the reference product, including moderate-to-severe persistent allergic asthma.
On the same day, Teva Pharmaceutical Industries Limited announced FDA approval of Ponlimsi as a biosimilar to Prolia. The company said the approval covers all indications of the reference product, including treatment of postmenopausal women with osteoporosis at high risk for fracture, supported by data showing comparable efficacy, safety, and immunogenicity.
Teva Pharmaceutical Industries Limited develops and markets generic and biopharmaceutical medicines globally.
1. Delta Air Lines, Inc. (NYSE:DAL)
On April 9, 2026, TD Cowen raised the price target on Delta Air Lines, Inc. (NYSE:DAL) to $84 from $76 and maintained a Buy rating after updating its model following a Q1 update. TD Cowen said fuel volatility highlights the durability of the company’s business and could raise the long-term RASM floor as weaker competitors pull back, while noting net debt is at its lowest level since pre-COVID.
Similarly, Citi raised its price target on Delta Air Lines, Inc. to $79 from $77 previously and maintained a Buy rating on the shares. Citi said the company delivered a Q1 earnings beat supported by strong demand trends, reinforcing its position across key market segments.
On April 8, 2026, Delta Air Lines, Inc. reported Q1 adjusted EPS of 64c compared to the 56c consensus estimate, with revenue of $15.85B versus $14.82B consensus. CEO Ed Bastian said results were “more than 40 percent higher” year over year despite higher fuel costs and operational disruptions, highlighting strong performance and $1.3B in profit-sharing payouts.
Delta Air Lines, Inc. provides passenger and cargo air transportation services globally.
READ NEXT: 10 Best Stocks That Beat Earnings Estimates and 10 Best 52-Week Low NASDAQ Stocks to Buy Now.
Hedge Fund Resource Center